Panbela announces pricing of approximately $15 million public offering

Minneapolis, jan. 26, 2023 (globe newswire) --  panbela therapeutics, inc. (nasdaq: pbla), (“panbela” or the “company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 6,675,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 13,350,000 shares of its common stock (the “public warrants”) at a purchase price of $2.25 per share and associated public warrant. the public warrants will have an exercise price of $2.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. the offering is expected to close on or about january 30, 2023, subject to customary closing conditions.
PBLA Ratings Summary
PBLA Quant Ranking